1. Krebs-Brown A, Munafo A, Gaikwad S, Urgatz B, Castello-Bridoux C. Comment on: “Why were more than 200 subjects required to demonstrate the bioequivalence of a new formulation of levothyroxine with an old one?”. Clin Pharmacokinet. 2019. https://doi.org/10.1007/s40262-019-00847-0.
2. Anonymous. Status of EMEA scientific guidelines and European pharmacopoeia monographs and chapters in the regulatory framework applicable to medicinal products. 2008. https://www.ema.europa.eu/en/documents/scientific-guideline/status-emea-scientific-guidelines-european-pharmacopoeia-monographs-chapters-regulatory-framework_en.pdf. Accessed 21 Nov 2019.
3. Anonymous. Concept paper on the development of product-specific guidance on demonstration of bioequivalence. 2013. https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-product-specific-guidance-demonstration-bioequivalence_en.pdf. Accessed 21 Nov 2019.
4. Anonymous. An open-label, single-dose, randomized, two-period, two-sequence crossover, single-center trial to assess bioequivalence of 600 µg Ievothyroxine new formulation versus old formulation administered orally as 3 white tablets of 200 µg in healthy volunteers. 2014. https://ansm.sante.fr/var/ansm_site/storage/original/application/3606e51c6c64f05e25565a3c5bf840b7.pdf. Accessed 21 Nov 2019.
5. Anonymous. Draft guidance on levothyroxine sodium (p. 2). 2018. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM428208.pdf. Accessed 4 Oct 2019.